Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Evidence of central retinal vein occlusion, defined as documented retinal hemorrhage into all four quadrants with dilated veins, or branch retinal vein occlusion, as documented on clinical exam * Age 18 years or over * Central macular edema on clinical exam as well as imaging with a central thickness of ≥ 250 microns * Visual acuity ranging from 20/8000 to 20/40 * Media clarity and patient cooperation sufficient to allow adequate testing utilizing OCT and FA * No previous treatment that might compromise or confound assessment of the study outcomes * Ability to speak and read English Exclusion Criteria: * Acute illness or cognitive or other impairment that, in the opinion of the investigator, would interfere with study requirements * Concurrent ocular conditions likely to significantly compromise vision and contribute the macular compromise * History of grid/focal laser in the study eye * History of vitreal surgery * Previous treatment with triamcinolone acetonide in either eye * Previous use of bevacizumab, pegaptanib, or ranibizumab in either eye * Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders * History of cerebrovascular accident within 1 year prior to Day 0 * Inability to comply with study or follow-up procedures * Any cognitive defect as a result of mental disease, previous injury, or disease process that may interfere with interpretation of study results * Visual acuity better than 20/40 * Pregnancy (positive pregnancy test) or lactation * Inadequate contraception in premenopausal women